Gain Therapeutics (GANX) Expected to Announce Earnings on Thursday

Gain Therapeutics (NASDAQ:GANX) is expected to be announcing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Gain Therapeutics Trading Down 25.6%

Shares of NASDAQ:GANX opened at $1.95 on Thursday. The company has a 50 day moving average of $2.16 and a 200-day moving average of $2.36. The company has a current ratio of 2.52, a quick ratio of 2.52 and a debt-to-equity ratio of 0.05. The firm has a market cap of $75.00 million, a P/E ratio of -3.20 and a beta of -0.03. Gain Therapeutics has a twelve month low of $1.41 and a twelve month high of $4.34.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on GANX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a research report on Friday, December 19th. Finally, Roth Mkm reissued a “buy” rating and issued a $10.00 price objective on shares of Gain Therapeutics in a research note on Friday, December 19th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Institutional Trading of Gain Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in GANX. Marshall Wace LLP lifted its stake in Gain Therapeutics by 849.3% during the fourth quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock valued at $5,353,000 after purchasing an additional 1,487,186 shares during the last quarter. Geode Capital Management LLC grew its position in Gain Therapeutics by 15.6% in the fourth quarter. Geode Capital Management LLC now owns 397,942 shares of the company’s stock worth $1,282,000 after buying an additional 53,796 shares during the last quarter. Jane Street Group LLC grew its position in Gain Therapeutics by 234.5% in the fourth quarter. Jane Street Group LLC now owns 242,328 shares of the company’s stock worth $780,000 after buying an additional 169,878 shares during the last quarter. State Street Corp increased its holdings in shares of Gain Therapeutics by 72.9% in the fourth quarter. State Street Corp now owns 157,537 shares of the company’s stock valued at $507,000 after buying an additional 66,400 shares in the last quarter. Finally, LPL Financial LLC bought a new position in shares of Gain Therapeutics in the fourth quarter valued at $343,000. 11.97% of the stock is currently owned by institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.